Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 2/20 | 0.76 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.59 |
| ▸ | RAF1 | P04049 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.53 |
| ▸ | CDK1 | P06493 | 1/20 | 0.53 |
| ▸ | SRC | P12931 | 1/20 | 0.53 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.53 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.53 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.53 |
| ▸ | HASPIN | Q8TF76 | 4/20 | 0.53 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.53 |
| ▸ | CDK9 | P50750 | 2/20 | 0.53 |
| ▸ | APP | P05067 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | SNCA | P37840 | 2/20 | 0.51 |
| ▸ | FLT3 | P36888 | 2/20 | 0.48 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.48 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.48 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6288777 | 1.00 | CHEK1 (0.76) | CHEK1NTRK1RAF1KMT2ACHEK2 | |
| SCHEMBL8464120 | 0.86 | CHEK1 (1.00) | CHEK1NTRK1KMT2ACHEK2CDK1 | |
| SCHEMBL5790649 | 0.86 | NTRK1 (0.67) | CHEK1NTRK1RAF1KMT2AAPP | |
| SCHEMBL5790646 | 0.86 | NTRK1 (0.67) | CHEK1NTRK1RAF1KMT2AAPP | |
| SCHEMBL857064 | 0.86 | CHEK1 (1.00) | CHEK1NTRK1KMT2ACHEK2CDK1 | |
| SCHEMBL8464117 | 0.86 | CHEK1 (1.00) | CHEK1NTRK1KMT2ACHEK2CDK1 | |
| SCHEMBL12537519 | 0.86 | NTRK1 (0.67) | CHEK1NTRK1RAF1KMT2AAPP | |
| SCHEMBL8320628 | 0.82 | CHEK1 (0.53) | CHEK1NTRK1RAF1KMT2ACHEK2 | |
| SCHEMBL8321481 | 0.82 | CHEK1 (0.53) | CHEK1NTRK1RAF1KMT2ACHEK2 | |
| SCHEMBL8319684 | 0.79 | CHEK1 (0.50) | CHEK1NTRK1RAF1KMT2ACHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030082519-A1 | Cellular kinases involved in Cytomegalovirus infection and their inhibition | AXXIMA PHARMACEUTICALS AG (DE) | 2003-05-01 | — | — | US | claimed |
| EP-0741726-B1 | SUBSTITUTED 3-ARYLIDENE-7-AZAOXINDOLE COMPOUNDS AND PROCESS FOR THEIR PREPARATION | PHARMACIA & UPJOHN SPA (IT) | 1999-11-17 | — | — | EP | claimed |
| EP-0741726-A1 | SUBSTITUTED 3-ARYLIDENE-7-AZAOXINDOLE COMPOUNDS AND PROCESS FOR THEIR PREPARATION | PHARMACIA & UPJOHN S.p.A. (IT) | 1996-11-13 | — | — | EP | claimed |
| WO-1996016964-A1 | SUBSTITUTED 3-ARYLIDENE-7-AZAOXINDOLE COMPOUNDS AND PROCESS FOR THEIR PREPARATION | PHARMACIA & UPJOHN S.P.A (IT) | 1996-06-06 | — | — | WO | claimed |
| US-6849409-B2 | Cellular kinases involved in Cytomegalovirus infection and their inhibition | AXXIMA PHARMACEUTICALS AG (DE) | 2005-02-01 | — | — | US | disclosed |
| US-20030082519-A1 | Cellular kinases involved in Cytomegalovirus infection and their inhibition | AXXIMA PHARMACEUTICALS AG (DE) | 2003-05-01 | — | — | US | disclosed |
| EP-0741726-B1 | SUBSTITUTED 3-ARYLIDENE-7-AZAOXINDOLE COMPOUNDS AND PROCESS FOR THEIR PREPARATION | PHARMACIA & UPJOHN SPA (IT) | 1999-11-17 | — | — | EP | disclosed |
| US-5719135-A | TYROSINE KINASE INHIBITORS | PHARMACIA S.P.A. (IT) | 1998-02-17 | — | — | US | disclosed |
| EP-0741726-A1 | SUBSTITUTED 3-ARYLIDENE-7-AZAOXINDOLE COMPOUNDS AND PROCESS FOR THEIR PREPARATION | PHARMACIA & UPJOHN S.p.A. (IT) | 1996-11-13 | — | — | EP | disclosed |
| WO-1996016964-A1 | SUBSTITUTED 3-ARYLIDENE-7-AZAOXINDOLE COMPOUNDS AND PROCESS FOR THEIR PREPARATION | PHARMACIA & UPJOHN S.P.A (IT) | 1996-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030082519-A1 | Cellular kinases involved in Cytomegalovirus infection and their inhibition | CDC42BPG, CDC42BPB, CDC7 | CHEK1 41/4885NTRK1 2793/4885RAF1 477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.